Palmsten Kristin, Flores Katrina F, Chambers Christina D, Weiss Lauren A, Sundaram Rajeshwari, Buck Louis Germaine M
1 Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA.
2 Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA.
Reprod Sci. 2018 Jan;25(1):94-101. doi: 10.1177/1933719117702249. Epub 2017 Apr 12.
To identify frequently reported prescription medications and supplements among couples planning pregnancy because there is a lack of descriptive information on these agents in women and men who are trying to conceive.
Five hundred one couples enrolled in the Longitudinal Study of Infertility and the Environment, which took place between 2005 and 2009. Participants reported prescription medications as well as prescription and over-the-counter supplements used through interviews at study enrollment and through daily dairies during the 12-month follow-up. We identified prescription medications and supplements prospectively reported by ≥1% of women and men at baseline and from daily journal information grouped into 3-month preconception follow-up intervals while couples tried for pregnancy.
The 5 most reported prescription medications among women were levothyroxine (5.8%), cetirizine (2.6%), fluticasone (2.4%), escitalopram (1.8%), and fluoxetine (1.8%) and for men were lisinopril (2.0%), mometasone (2.0%), fexofenadine (1.8%), atorvastatin (1.6%), and montelukast (1.6%). The most reported supplements were multivitamins (63.3%, 43.5%) and fish oil (13.2%, 9.4%) for women and men, respectively, and prenatal vitamins (22.0%) for women. For women during the first 3 months of follow-up, prenatal vitamins (6.0%) and antibiotics (1.2%-2.6%) were among the most frequently started medications. During the next 3 months, clomiphene (4.5%) was the most frequently initiated medication.
Couples trying for pregnancy reported a variety of prescription medications and supplements, and they differed by gender. Preconception guidance should address medication and supplement use to avoid potential exposures associated with adverse reproductive and perinatal outcomes.
鉴于试图受孕的女性和男性缺乏关于这些药物的描述性信息,确定计划怀孕的夫妇中经常报告的处方药和补充剂。
501对夫妇参与了2005年至2009年期间进行的不孕与环境纵向研究。参与者在研究入组时通过访谈以及在12个月的随访期间通过每日日记报告了处方药以及使用的处方药和非处方药补充剂。我们前瞻性地确定了在基线时以及在夫妇尝试怀孕期间按3个月孕前随访间隔分组的每日日记信息中,≥1%的女性和男性报告的处方药和补充剂。
女性中报告最多的5种处方药是左甲状腺素(5.8%)、西替利嗪(2.6%)、氟替卡松(2.4%)、艾司西酞普兰(1.8%)和氟西汀(1.8%),男性中报告最多的是赖诺普利(2.0%)、莫米松(2.0%)、非索非那定(1.8%)、阿托伐他汀(1.6%)和孟鲁司特(1.6%)。报告最多的补充剂分别是女性的多种维生素(63.3%,43.5%)和男性的鱼油(13.2%,9.4%),以及女性的产前维生素(22.0%)。在随访的前3个月,女性中最常开始使用的药物是产前维生素(6.0%)和抗生素(1.2% - 2.6%)。在接下来的3个月中,氯米芬(4.5%)是最常开始使用的药物。
尝试怀孕的夫妇报告了多种处方药和补充剂,且存在性别差异。孕前指导应涉及药物和补充剂的使用,以避免与不良生殖和围产期结局相关的潜在暴露。